Poltreg S.A.. (3/11/24). "Press Release: Poltreg’s State-of-the-Art Manufacturing Facility Has Received Approval to Produce Cellular Therapies from the Chief Pharmaceutical Inspectorate in Poland".

	Region	Gdansk (Danzig)
	Country	Poland
	Organisation	Poltreg S.A.
	Organisation 2	Poland (govt)
	Product	PTG-007 Treg cell therapy (Poltreg)
	Product 2	contract manufacturing (biologicals)

PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellular therapies (or Advanced Therapy Medicinal Products) from the Chief Pharmaceutical Inspectorate in Poland.

We can now seek permission to perform clinical trials at the site, including for diseases such as Type-1 Diabetes (T1D) and Multiple Sclerosis with our lead asset PTG-007.

PolTREG has more than 17 years of experience treating patients. We have administered Treg cells to more than 100 people over that period, either in hospital exemption procedures or in clinical trials.

Our state-of-the-art manufacturing facility contains:

15 stand-alone production lines
annual capacity of 1500 therapies
4000 sq. m of space

Record changed: 2024-04-19

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

More documents for Poltreg S.A.

[1] Poltreg S.A.. (2/21/24). "Press Release: Poltreg Appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to Help It Build Partnerships across Industry and Deliver Milestones"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]